Analyst: Genmab's arbitration defeat could disappoint some in the market
An analyst previously did not think that Genmab’s legal loss would lead to a market reaction, but now he’s not so sure.
by marketwire, translated by daniel pedersen
A new defeat for Genmab in an arbitration case against its partner, Janssen, concerning the rights to best-seller cancer drug Darzalex Faspro, risks putting pressure on the Danish biotech company’s stock, assesses an analyst.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab's new arbitration against Janssen denied in court
For subscribers
New arbitration full of upsides for Genmab, says analyst
For subscribers
